Real-World Evidence Shows Oral INVOKANA ® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Invokana | Pharmaceuticals | Weight Loss